Corrigendum: Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening

Front Immunol. 2024 Dec 3:15:1514836. doi: 10.3389/fimmu.2024.1514836. eCollection 2024.

Authors

Siyu Zhang¹, Changxin Huang¹, Yongqiang Li¹, Zhaoyang Li¹, Ying Zhu², Lili Yang¹, Haokun Hu¹, Quan Sun¹, Mengmeng Liu³, Songqiang Cao⁴

Affiliations

¹ Department of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
² Department of Clinical Hematology and Transfusion, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
³ Department of Psychiatry and Psychology, 155 Hospital of Kaifeng City, Kaifeng, China.
⁴ Department of Urology, Huaihe Hospital of Henan University, Kaifeng, China.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2024.1473145.].

Keywords: MHC molecular affinity; colorectal cancer; neoantigen; tumor immunotherapy; tumor vaccine.

Copyright © 2024 Zhang, Huang, Li, Li, Zhu, Yang, Hu, Sun, Liu and Cao.

Publication types

Published Erratum